Alliances

Boehringer Ingelheim

In summer 2012, Polyphor Ltd announced the signing of a research collaboration and license agreement with Boehringer Ingelheim International GmbH, under which Polyphor applies its proprietary MacroFinder® drug discovery technology to identify and optimize novel macrocyclic drug candidates addressing therapeutic targets selected by Boehringer Ingelheim. In return, Polyphor receives from Boehringer Ingelheim an up-front payment, research funding and milestone payments as candidate molecules progress through the drug discovery process, preclinical and clinical development and onto the market. In addition, Polyphor is eligible for undisclosed royalties on the commercial sales of any approved products.

Novartis

In spring 2010, Polyphor Ltd and Novartis Pharma AG, a Swiss corporation having its principal place of business in Basel, Switzerland, entered into a Collaboration and Licensing Agreement. Under the terms of the collaboration, Polyphor will apply its proprietary PEM (Protein Epitope Mimetics) drug discovery technology to identify novel PEMdrug candidates against drug targets of interest to Novartis. Novartis provides Polyphor with an upfront payment, research funding and milestone payments as candidate molecules progress through the drug discovery process, preclinical and clinical development and onto the market. In addition, Polyphor is eligible to receive royalties on the commercial sales of approved products.